“Helping life sciences companies capture opportunities in Singapore and Southeast Asia, focusing on product development and market penetration strategies.”
Dr. Ivan Seah, MD
A physician by background, Ivan has extensive knowledge and experience in addressing therapeutic needs. Prior to consulting, he provided care for patients in specialities including orthopaedics, internal medicine, general surgery and ophthalmology. Having previous assisted a broad range of clients including financial institutes and venture-backed biotechnology companies, Ivan brings onboard BCS both pre-clinical and clinical product development expertise as well as biotechnology market insights.
His expertise in the areas of ophthalmology, cell and gene therapy as well as biomaterials have supported clients in developing R&D and investment portfolio strategies. Ivan keeps up with ongoing technological developments by being active in academia and has published over 20 internationally peer-reviewed articles in high impact factor journals like Advanced Materials (IF 30.85), The Journal of Clinical Investigation (IF 12.28), Proceedings of the National Academy of Sciences (IF 9.58), Ophthalmology (IF 8.2) and JAMA Ophthalmology (IF 6.7).
He has received multiple accolades and recognitions in his career including being selected in 2020 as one of the 100 Leaders of Tomorrow by the Global Biotech Revolution and admission into the Clinton Global Initiative University Class of 2021.
Examples of his recent consulting work include:
- Due Diligence: Advised a US-based financial institution client on investment decision of a target biotechnology company
- Investment Portfolio Strategy: Advised an investment group on developing a portfolio in a specific technology niche through market analysis
- Preclinical R&D Strategy: Supported multiple international biotechnology companies in developing R&D strategy focusing on IND-enabling activities
- Clinical Trial Strategy: Supported a biotechnology company in developing first-in-man clinical trial design